MedTrace Logo

Comparative Pharmacokinetics (PK) Study of Efavirenz or Lopinavir/Ritonavir Between Older and Younger HIV-Infected Adults

NCT00179335 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 45

Last updated 2021-04-26

No results posted yet for this study

Summary

HIV infected patients, aged \</= 35 years and aged \>/= 55 years, who are regularly taking either efavirenz (EFV) or lopinavir/ritonavir (Lop/r) as part of their antiretroviral regimen are being asked to spend 12 hours at the researchers' clinic (the ACS clinic at Jacobi Medical Center, Bronx, New York) for an intensive pharmacokinetic study in which 5 cc of blood will be drawn 9 times over a 12 hour period. Patients taking EFV will return for one additional blood draw the following day.

Conditions

  • HIV Infections

Interventions

PROCEDURE

Blood drawing to determine drug levels

Sponsors & Collaborators

  • Abbott

    collaborator INDUSTRY

  • University of Alabama at Birmingham

    collaborator OTHER

  • Albert Einstein College of Medicine

    lead OTHER

Principal Investigators

  • Elizabeth R Jenny-Avital, MD · Jacobi Medical Center, Albert Einstein College of Medicine

  • Edward Acosta, Pharm D · University of Alabama at Birmingham

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-08-31
Primary Completion
2006-01-31
Completion
2006-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00179335 on ClinicalTrials.gov